Functional consequences of iron overload in catecholaminergic interactions: The Youdim factor

Neurochemical Research

Volumn 32, Issue 10, 2007, Pages 1625-1639

  Archer, Trevor ^a,b,c   Fredriksson, Anders ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Basal ganglia; Behavioural deficits; Clozapine; DA D2 receptor supersensitivity; Fe2+; Haloperidol; Iron administration; Locomotion; Motor deficits; Postnatal; Rearing; Total activity; Vehicle

Indexed keywords

CLOZAPINE; HALOPERIDOL; IRON; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN REGION; CATECHOLAMINE NERVE CELL; COMORBIDITY; CONTROLLED STUDY; FEMALE; HYPERACTIVITY; IRON OVERLOAD; MALE; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENALIN BRAIN LEVEL; PRIORITY JOURNAL; PSYCHOSIS;

ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CATECHOLAMINES; CLOZAPINE; DENERVATION; DOPAMINE; DOPAMINE AGENTS; FEMALE; HALOPERIDOL; IRON; IRON OVERLOAD; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MOVEMENT DISORDERS; MPTP POISONING; NOREPINEPHRINE; PREGNANCY; PSYCHOTIC DISORDERS; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ANIMALIA; MUS;

EID: 34548796651     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9358-1     Document Type: Article

References (108)

1. Mash DC, Pablo J, Buck BE, Sanchez-Ramos J, Weiner WJ (1991) Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp Neurol 114:73-81
2. Hallgren B, Sourander P (1958) The effect of age on the non-haem iron in the brain. J Neurochem 3:41-46
3. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953-1975
4. Janetzky B, Reichmann H, Youdim MBH, Riederer P (1997) Iron and oxidative damage in neurodegenerative diseases. In: Willey-Liss, Inc., pp. 407-421
5. Youdim MBH, Ben-Shachar D, Riederer P (1991) Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 31:34-40
6. Youdim MBH (1990) Neuropharmacological and neurochemical aspects of iron deficiency. In: Dobbing J (Ed) Brain behaviour and iron in the infant diet. Springer-Verlag, Berlin, pp 83-94
7. Youdim MBH, Riederer P (1997) Understanding Parkinson's disease. Sci Am 257:59-62
8. Youdim MBH, Riederer P (1999) Iron in the brain, normal and pathological. In: Adelman G, Smith BH (Eds) Encyclopedia of neuroscience. Elsevier, Amsterdam, pp 983-997
9. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863-873
10. Youdim MBH (2000) Nutrient deprivation and brain function: iron. Nutrition 16:504-508
11. Yehuda S, Youdim MBH, Mostofsky M (1986) Brain iron deficiency causes reduced learning capacity in rats. Pharmacol Biochem Behav 24:141-146
12. Ben-Shachar D, Youdim MB (1990) Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. J Neurochem 54:1136-1141
13. Ben-Shachar D, Pinhassi B, Youdim MB (1991) Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment. Eur J Pharmacol 202:177-183
14. Evans PH (1993) Free radicals in brain metabolism and pathology. Br Med Bull 49:577-587
15. Olanow CW (1992) Magnetic-resonance-imaging in parkinsonism. Neurol Clin 10:405-420
16. Strong R, Mattamal M, Andorn A (1993) Free radicals in aging. In: Free radicals, the aging brain, and age-related neurodegenerative disorders. CRC Press, Florida, pp 223-246
17. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 134(Suppl):69-78
18. Reichmann H, Janetzky B, Riederer P (1995) Iron-dependent enzymes in Parkinson's disease. J Neural Transm Suppl 46:157-164
19. Swaiman KF (1991) Hallervorden-Spatz syndrome and brain iron metabolism. Arch Neurol 48:1285-1293
20. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in postmortem parkinsonian brain [letter]. Lancet 2:1219-1220
21. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S (1986) Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 159:493-498
22. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63:793-807
23. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520
24. Youdim MBH, Fridkin M, Zheng H (2004) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transm 111:1455-1471
25. Youdim MBH, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson's disease and other neurodegenerative disease with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306-325
26. Zheng H, Weiner LM, Bar-Am O, Epsztejn M, Cabantchik I, Warshawsky A, Youdim MBH, Fridkin M (2005) Design, synthesis and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in neurodegenerative diseases. Bioorg Med Chem 13:773-783
27. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MBH (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68-78
28. Taylor EM, Morgan EH (1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Brain Res Dev Brain Res 55:35-42
29. Taylor EM, Crowe A, Morgan EH (1991) Transferrin and iron uptake by the brain: effects of altered iron status. J Neurochem 57:1584-1592
30. Dwork AJ, Lawler G, Zybert PA, Durkin M, Osman M, Willson N, Barkai AI (1990) An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res 518:31-39
31. Davison AN, Dobbing J (1968) Applied neurochemistry. Blackwell, Oxförd, pp 178-221, 253-316
32. Bolles RG, Woods PJ (1964) The ontogeny of behaviour in the albino rat. Anim Behav 12:427-441
33. Campbell BA, Lytle LD, Fibiger HC (1969) Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat. Science 166:635-637
34. Randall PK, Severson JA, Finch CE (1981) Aging and the regulation of striatal dopaminergic mechanisms in mice. J Pharmacol Exp Ther 219:695-700
35. McKenzie RG, Zigmond MJ (1985) Chronic neuroleptic treatment increased D-2 but not D-1 receptors in the rat striatum. Eur J Pharmacol 113:159-165
36. Tarsy D, Baldessarini RJ (1974) Behavioural supersensitivity to apomorphine following treatment with drugs which interfere with synaptic function of catecholamines. Neuropharmacology 13:927-940
37. Von Voigtlander PF, Losey EG, Triezenberg HF (1975) Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther 193:88-94
38. Randall PK (1985) Quantification of dopaminergic supersensitivity using apomorphine induced behaviour in the mouse. Life Sci 37:1419-1423
39. Scatton B (1977) Differential regional development of the tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur J Pharmacol 46:363-369
40. Laduron P, De Bie K, Leysen J (1977) Specific effect of haloperidol on dopamine turnover in the frontal cortex. Naunyn Schmiedelbergs Arch Pharmacol 296:183-185
41. Matsumoto T, Uchimura H, Hirano M, Soo Kim J, Yokoo H, Shimomura M, Nakahara T, Inoue K, Oomagari K (1983) Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete levels of rat brain. Eur J Pharmacol 89:27-33
42. Campbell A, Baldessarini RJ (1981) Tolerance to behavioural effects of haloperidol. Life Sci 29:1341-1346
43. Reynolds GP, Brown JE, McCall JE, McKay AVP (1992) Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: a postmortem study. J Neural Transm 87:225-230
44. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM (2003) Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiat 15:33-48
45. Lieberman JA (1998) Maximizing clozapine therapy: managing side effects. J Clin Psychiat 59:38-43
46. Archer T, Fredriksson A (2000) Effects of clonidine and adrenoceptor antagonists on motor activity in DSP4-treated mice I: dose, time- and parameter-dependency. Neurotoxicity Res 1:235-247
47. Archer T, Fredriksson A (2001) Effects of α-adrenoceptor agonists in chronic morphine administered DSP4-treated rats: evidence for functional cross-sensitization. Neurotoxicity Res 3:411-432
48. Archer T, Ögren S-O, Johansson G, Ross SB (1982) DSP4-induced two-way active avoidance impairment: involvement of central and not peripheral noradrenaline depletion. Psychopharmacology 76:303-309
49. Archer T, Mohammed AK, Ross SB, Söderberg U (1983) T-maze learning, spontaneous activity and food intake recovery following systemic administration of the noradrenaline neurotoxin, DSP4. Pharmacol Biochem Behav 19:121-130
50. Archer T, Jonsson G, Ross SB (1984) A parametric study of the effects of the noradrenaline neurotoxin DSP4 on avoidance acquisition and noradrenaline neurons in the CNS of the rat. Br J Pharmacol 82:249-257
51. Archer T, Fredriksson A, Jonsson G, Lewander T, Mohammed AK, Ross SB, Soderberg U (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 88:141-146
52. Dooley DJ, Bittiger H, Hauser KL, Bischoff SL, Waldmeier PC (1983) Alteration of central alpha 2- and beta-adrenergic receptors in the rat after DSP4, a selective noradrenergic neurotoxin. Neuroscience 9:889-898
53. Frderiksson A, Archer T (2000) Effects of clonidine and α-adrenoceptor antagonists on motor activity in DSP4-treated mice II: interactions with apomorphine. Neurotoxicity Res 1:249-259
54. Jonsson G, Hallman H (1982) Response of central monoamine neurons following an early neurotoxic lesion. Bibl Anat 23:76-92
55. Jonsson G, Hallman H, Ponzio F, Ross SB (1981) DSP4 (N-(2-chloroethyl)-N- ethyl-2-bromobenzylamine)-a useful denervation tool for central and peripheral noradrenaline neurons. Europ J Pharmacol 72:173-188
56. Jonsson G, Hallman H, Sundström E (1982) Effects of the noradrenaline neurotoxin DSP4 on the postnatal development of central noradrenaline neurons in the rat. Neuroscience 7:2895-2907
57. Ponzio F, Hallman H, Jonsson G (1981) Noradrenaline and dopamine interaction in rat brain during development. Med Biol 59:161-169
58. Ross SB (1976) Long-term effects of N-2-chloroethyl-N-ethyl-2- bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart. Brit J Pharmacol 58:521-527
59. Ross SB, Renyi L (1976) On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4) on the active uptake of noradrenaline. J Pharmacol Pharmac 28:458-459
60. Archer T, Jonsson G, Ross SB (1985) Active and passive avoidance following the administration of systemic DSP4, xylamine, or p-chloroamphetamine. Behav Neural Biol 43:238-249
61. Archer T (1982) Serotonin and fear retention in the rat. J Comp Physiol Psychol 96:491-516
62. Archer T, Jonsson G, Minor BG, Post C (1986) Noradrenergic-serotonergic interactions and nociception in the rat. Europ J Pharmacol 120:295-307
63. Heal DJ, Butler SA, Prow MR, Buckett WR (1993) Quantification of alpha 2-adrenoceptors in rat brain after short-term DSP-4 lesioning. Europ J Pharmacol 249:37-41
64. Post C, Persson ML, Archer T, Minor BG, Danysz W, Sundström E (1987) Increased antinociception by alpha-adrenoceptor drugs after spinal cord noradrenaline depletion. Europ J Pharmacol 137:107-116
65. Dooley DJ, Mogilnicka E, Delini-Stula A, Waechter F, Truog A, Wood J (1983) Functional supersensitivity to adrenergic agonists in the rat after DSP-4, a selective noradrenergic neurotoxin. Psychopharmacology 81:1-5
66. Fornai F, Bassi L, Torracca MT, Alessandri MG, Scalori V, Corsini GU (1996) Region- and neurotransmitter-dependent species and strain differences in DSP4-induced monoamine depletion in rodents. Neurodegeneration 5:241-249
67. Langston JW (1985) MPTP neurotoxicity: an overview and characterization of phases of toxicity. Life Sci 36:201-206
68. Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T (1990) MPTP-induced hypoactivity in mice: reversal by L-Dopa. Pharmacol Toxicol 67:295-301
69. Sundström E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioural changes in MPTP-lesioned C57 Bl/6 mice: a model for Parkinson's disease. Brain Res 528:181-188
70. Heikkila RE, Sieber B-A, Manzino L, Sonsalla PK (1989) Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10:171-183
71. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Europ J Pharmacol 129:339-345
72. Archer T, Fredriksson A (2003) An antihypokinesic action of α2-adrenoceptors upon MPTP-induced behaviour deficits in mice. J Neural Transm 110:183-200
73. Fredriksson A, Archer T (1994a) MPTP-induced behavioural deficits in mice: validity and utility of a model of parkinsonism. In Palomo T, Archer T, Beningen RJ (eds) Strategies for studying brain disorders, vol 2, Schizophrenia, movement disorders and age-related disorders. University Press, Madrid, pp 201-231
74. Fredriksson A, Archer T (1994b) MPTP-induced behavioural and biochemical deficits: a parametric analysis. J Neurol Transm 7:123-132
75. Fredriksson A, Palomo T, Chase TN, Archer T (1999) Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. J Neural Transm 106:283-300
76. Fredriksson A, Schroder N, Eriksson P, Izquierdo I, Archer T (1999) Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol Appl Pharmacol 159:25-30
77. Fredriksson A, Archer T (2003) Effect of postnatal iron administration on MPTP-induced behavioural deficits and neurotoxicity: behavioural enhancement by L-Dopa-MK-801 co-administration. Behav Brain Res 139:31-46
78. Fredriksson A, Schroder N, Eriksson P, Izquierdo I, Archer T (2001) Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkinsonism Rel Dis 7:97-105
79. Persson T, Waldeck B (1970) Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brain. Europ J Pharmacol 11:315-320
80. Andén N-E, Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. Europ J Pharmacol 39:275-282
81. Fornai F, Alessandri MG, Torracca MT, Bassi L, Corsini GU (1997) Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J Pharmacol Exp Ther 283:100-107
82. Marien MR, Briley M, Colpaert FC (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Europ J Pharmacol 236:487-489
83. Nishi K, Kondo T, Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa. Neurosci Lett 123:244-247
84. Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 13:655-669
85. Björk L, Cornfield LJ, Nelson DL, Hillver S-E, Andén N-E, Lewander T, Hacksell U (1991) Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Therap 258:58-65
86. Ye Liu Y, Yu H, Mohell N, Nordvall G, Lewander T, Hacksell U (1995) Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine-D2-receptor antagonists. J Med Chem 38:150-160
87. Kirk R (1995) Experimental design: procedures for the behavioural sciences. Brooks/Cole, Belmont, CA
88. Fredriksson A, Eriksson P, Archer T (2006) Postnatal Iron-induced motor behaviour alterations following chronic neuroleptic administration in mice. J Neural Transm 113:137-150
89. Fredriksson A, Archer T (2006) Subchronic administration of haloperidol influences the functional deficits of postnatal iron administration in mice. Neurotoxicity Res 10:123-129
90. Archer T, Fredriksson A (2006) Influence of noradrenaline denervation on MPTP-induced deficits in mice. J Neural Transm 113:1119-1129
91. Archer T, Schröder N, Fredriksson A (2003) Neurobehavioural deficits following postnatal iron overload: II Instrumental learning performance. Neurotoxicity Res 5:77-94
92. Fredriksson A, Schroder N, Eriksson P, Izquierdo I, Archer T (2000) Maze learning and motor activity deficits in adult mice induced by iron exposure during a critical postnatal period. Brain Res Dev Brain Res 119:65-74
93. Fredriksson A, Schroder N, Archer T (2003) Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity. Neurotoxicity Res 5:53-76
94. Fredriksson A, Archer T (2002) Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration. Amino Acids 23:111-132
95. Schröder N, Fredriksson A, Vianna MR, Roesler R, Izquierdo I, Archer T (2001) Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 124:77-85
96. Archer T, Palomo T, Fredriksson A (2002) Functional deficits following neonatal dopamine depletion and isolation housing: circular water maze acquisition under pre-exposure conditions and motor activity. Neurotox Res 4:503-522
97. Ben-Shachar D, Livne E, Spanier I, Zuk R, Youdim MB (1993) Iron modulates neuroleptic-induced effects related to the dopaminergic system. Isr J Med Sci 29:587-592
98. Yehuda S, Youdim MBH (1989) Brain iron: a lesion from animal models. Am J Clin Nutr 50(Suppl):618-621
99. Ögren S-O, Archer T (1994) Effects of typical and atypical antipsychotic drugs on two-way active avoidance: relationship to DA receptor blocking profile. Psychopharmacology 114:383-391
100. Richelson E, Elson A (1984) Antagonism of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103:197-214
101. Waddington JL (1990) Neuroleptic/dopamine receptors. Eur J Pharmacol 183:106
102. Meltzer HR, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of D1-D2 and serotonin PK1 values. J Pharmacol Exp Ther 251:3238-3246
103. Berridge CW, Dunn AJ (1990) DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behaviour 3 and 14 days after treatment. Psychopharmacology 100:504-508
104. Marien MR, Colpaert FC, Rosenquist AC (2004) Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 45:38-78
105. Archer T, Bassen M, Peters D, Luthman J, Fredriksson A (1996) Dopaminergic-glutamatergic balance in the forebrain: functional studies of movement disorders in rats and mice. In: Beninger RJ, Palomo T, Archer T (eds) Dopamine disease states. Madrid University Press, Madrid, pp 117-154
106. Archer T, Fredriksson A (1999) Effects of acute/chronic, subthreshold/threshold doses of L-Dopa in MPTP-treated mice: I influence of competitive and noncompetitive NMDA antagonists. In: Palomo T, Beninger RJ, Archer T (eds) Interactive monoaminergic disorders. Editorial Sintesis, Madrid, pp 573-606
107. Youdim MBH, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease [published erratum appears in Mov Disord 1993 Apr;8(2):255]. Mov Disord 8:1-12
108. Youdim MBH, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann N Y Acad Sci 890:7-25